Privia Health Group Inc

Privia Health Group Inc maintains a strong liquidity position, with $479.69 million in cash and equivalents, representing 35% of total assets. The company has no long-term debt and a current ratio of 1.6, indicating a solid ability to meet short-term obligations. The price-to-book ratio of 3.84 suggests the market values the company at a premium to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible asset discount. Profitability metrics show a return on equity (ROE) of 3.11% and a return on assets (ROA) of 1.67%, both below the industry median for healthcare services providers. The company's operating margin is 1.61% (calculated from operating income of $34.24 million on $2.12 billion in revenue), which is significantly lower than the industry median of 6.5%. This suggests operational inefficiencies or competitive pricing pressures. Geographically, Privia Health's revenue is concentrated in the United States, with no material international exposure disclosed. Segment-wise, the company operates as a single reportable segment, with no material diversification across product lines or geographic regions. This concentration increases exposure to regional economic and regulatory shifts. The company's revenue growth outlook for the current fiscal year is flat, with no significant year-over-year increase expected. Free cash flow of $39.67 million is modest relative to revenue, limiting reinvestment capacity. The absence of long-term debt and the presence of $479.69 million in cash suggest the company is not capital-intensive and may not require significant reinvestment in the near term. Risk factors include low liquidity and dilution risk, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.0 indicates no leverage, reducing financial risk but also limiting potential returns in a rising interest rate environment. The absence of dilution risk is a positive, but the company's low ROE and ROA suggest underperformance relative to capital employed. Recent events include the release of Q4 2023 financial results, which showed a net income of $22.92 million on $2.12 billion in revenue. Analysts have set a mean price target of $31.50, with a median of $31.00, indicating a potential upside of 40% from the current market price of $22.55. The mean recommendation of 1.76 (on a 1-5 scale) suggests a generally positive outlook from analysts.